<DOC>
	<DOCNO>NCT00811616</DOCNO>
	<brief_summary>OBJECTIVES : The primary objective study assess safety efficacy Supralimus - Core™ Sirolimus Eluting Stent de novo native vessel obstructive coronary artery disease . STUDY DESIGN : This single centre , prospective study . Approximately 105 patient enrol study . Patients follow twelve month post-procedure . All patient repeat angiography 8 month . STUDY POPULATION : The study population consist approximately 105 patient de novo native vessel obstructive coronary artery disease specific criterion . Patients daily practice include . Patients meet eligibility criterion inclusion study . ENDPOINTS : The primary safety endpoint study define Major Adverse Cardiac Events ( MACE ) 30 day . The primary efficacy endpoint in-stent binary restenosis rate 8-month follow-up determine off-line Quantitative Coronary Angiography . The following secondary efficacy endpoint assess - Angiographic success - Procedure success - Quantitative Coronary Angiography derive vessel parameter in-stent 5 mm proximal 5 mm distal edge stent : acute gain , MLD , % DS , late loss , mean diameter . In-stent pre- , post 8-month follow-up . - Clinically justified Target Lesion Revascularization ( TLR ) 12 month The following secondary safety endpoint assess : - MACE 12 month - Device relate SAEs 12 month - Angiographic stent thrombosis : Subacute ( procedure 30 day ) Late ( 30 day 12 month )</brief_summary>
	<brief_title>A Safety Efficacy Supralimus™ Core™ Sirolimus Eluting Stent MAX DDHV Institute</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>The patient must &gt; = 18 year age ; Symptomatic ischemic heart disease ( CCS class 1 4 , Braunwald class IB , IC , IIB , IIC , IIIB , IIIC ) and/or objective evidence myocardial ischemia ; Vessel size &gt; = 2.5 &lt; = 3.5mm . Target lesion cover stent manner lesion stent ratio least 1.5 . Acceptable candidate coronary artery bypass surgery ( CABG ) ; Target lesion stenosis &gt; 50 % &lt; 100 % ( TIMI flow I ) ( visual estimate ) ; The patient inform nature study agree provision provide write informed consent , approve appropriate Medical Ethics Committee ( MEC ) Institutional Review Board ( IRB ) . Women childbearing potential ; Impaired renal function ( creatinine &gt; 2.0 mg/dl 177 µmol/l ) ; Any patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) ; Recipient heart transplant ; Restenotic lesion graft . Patient life expectancy le 12 month ; Known allergy aspirin , clopidogrel bisulphate ( Plavix ) , ticlopidine ( Ticlid ) , heparin stainless steel ; Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; Currently participate investigational drug another device study , subject inclusion another investigational drug another device study followup . Angiographic Exclusion criterion : Unprotected leave main coronary artery disease &gt; =50 % stenosis ; Angiographic evidence thrombus ( thrombus large half diameter vessel and/or require intervention angiojet , exciser , thrombolysis , etc . ) ; Ejection fraction &lt; = 30 % ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Supralimus-Core™</keyword>
	<keyword>de novo native coronary artery lesion</keyword>
</DOC>